02012nas a2200217 4500000000100000008004100001653001200042653001500054653001200069653002000081653002300101100001300124700001300137700001600150700001200166700001500178700001300193245009100206856007000297520142700367 2018 d10aAKR1B1010aBiomarkers10aleprosy10aReaction type 210aTherapeutic target1 aSoares C1 aFachin L1 aTrombone AP1 aRosa PS1 aGuidella C1 aBelone A00aPotential of AKR1B10 as a Biomarker and Therapeutic Target in Type 2 Leprosy Reaction. uhttps://www.frontiersin.org/articles/10.3389/fmed.2018.00263/full3 a
The AKR1B10 (aldo-keto reductase family 1 member B10) gene has important functions in carcinogen-induced neoplasia. AKR1B10 is also expressed in type 2 reaction leprosy patients (R2). We measured the expression of AKR1B10 in the skin lesions of patients with leprosy by immunohistochemistry from biopsies that encompassed the spectrum of types of leprosy, based on the Ridley and Jopling classification (10 samples each of tuberculoid [TT], borderline tuberculoid [BT], mid-borderline [BB], and borderline lepromatous [BL] lesions; four samples of lepromatous lesions [LL]), reactional leprosy (14 samples of type 1 Reaction [R1] and 10 samples of type 2 Reaction [R2]), and biopsies from 9 healthy control (HC) subjects. In addition, 46 lepromatous lesions (BL and LL), 45 lepromatous lesions in regression, and 115 R2 lesions were included. Eight of 10 R2 samples (80%), 3 of 46 active BL and LL samples (6%), 23 of 45 BL and LL samples in regression (51%), and 107 of 115 R2 samples (93%) were positive for AKR1B10, differing significantly between all groups (p < 0.05). AKR1B10 expression was highest in the cytoplasm of macrophages. Thus, AKR1B10 is overexpressed on the lepromatous side (BL and LL) in samples that are in regression, especially type 2 reaction-associated lesions, rendering it a potential marker of type 2 reactional episodes of leprosy and a target of drugs against reactional episodes.